ASCO

Biotech By Matthew Herper

With the right molecular signal, a cancer drug works in every patient

Pharma By Adam Feuerstein

Roche’s TIGIT troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target

Biotech By Angus Chen

Promising results reported for new generation of CAR-T immunotherapy for myeloma

Biotech By Matthew Herper

Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients

Biotech By Adam Feuerstein

With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment

Biotech By Adam Feuerstein

Virtual Event: The ASCO Recap, Live!

Biotech By Adam Feuerstein

Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?

Pharma By Adam Feuerstein

For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer

Biotech By Adam Feuerstein

Allogene’s blood cancer data show durability of off-the-shelf CAR-T cells

Pharma By Adam Feuerstein

With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease

Biotech By Adam Feuerstein

Merus drug shows potential as treatment for rare type of pancreatic cancer

Biotech By Adam Feuerstein

Virtual Event: The ASCO Recap, Live!

First Opinion By Maura McCarthy

Early diagnosis, not cancer drug breakthroughs, is the best way to fix the global scourge of breast cancer

Biotech By Adam Feuerstein

Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows

Biotech By Adam Feuerstein

AstraZeneca study results could change treatment for certain early-stage lung cancer patients

Biotech By Adam Feuerstein

Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study

Biotech By Adam Feuerstein

Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show

The Readout LOUD By Adam Feuerstein and Matthew Herper

Listen: A special episode from the halls of the ASCO meeting

Biotech By Adam Feuerstein and Matthew Herper

What you missed at ASCO? A lot, as cancer research hastens on

Biotech By Adam Feuerstein

At ASCO, targeted lung cancer drugs shrink tumors caused by rare genetic mutations

Biotech By Matthew Herper

Tempus, a well-funded company run by a Groupon billionaire, wants to get patients into clinical trials

Biotech By Adam Feuerstein

Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients

Health By Matthew Herper

The Affordable Care Act erased a racial disparity in cancer care, a new study says

Pharma By Matthew Herper

Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs

Biotech By Matthew Herper

Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t